EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 24 / Numéro 12 (Décembre 2008) Med Sci (Paris), 24 12 (2008) 1071-1076 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 24, Numéro 12, Décembre 2008
Page(s) 1071 - 1076
Section M/S revues
DOI https://doi.org/10.1051/medsci/200824121071
Publié en ligne 15 décembre 2008
  1. Baldwin RW. Tumour-specific immunity against spontaneous rat tumours. Int J Cancer 1966; 1 : 257–64. [Google Scholar]
  2. Baldwin RW. An immunological approach to cancer. Lav Ist Anat Istol Patol Univ Studi Perugia 1968; 28 : 65–85. [Google Scholar]
  3. Baldwin RW. Tumour-associated antigens and tumour-host interactions. Proc R Soc Med 1971; 64 : 1039–42. [Google Scholar]
  4. Machour N, Gilbert D, Vittecoq O, et al. Protéomique et autoanticorps. Med Sci (Paris) 2005; 21 : 759–64. [Google Scholar]
  5. Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005; 4 : 1123–33. [Google Scholar]
  6. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Nal Acad Sci USA 1995; 92 : 11810–3. [Google Scholar]
  7. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94 : 1914–8. [Google Scholar]
  8. Tureci O, Mack U, Luxemburger U, et al. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett 2006; 236 : 64–71. [Google Scholar]
  9. Fossa A, Berner A, Fossa SD, et al. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 2004; 59 : 440–7. [Google Scholar]
  10. Maio M, Coral S, Sigalotti L, et al. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J Clin Endocrinol Metab 2003; 88 : 748–54. [Google Scholar]
  11. Stockert E, Jager E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187 : 1349–54. [Google Scholar]
  12. Park S, Lim Y, Lee D, et al. Identification and characterization of a novel cancer/testis antigen gene CAGE-1. Biochim Biophys Acta 2003; 1625 : 173–82. [Google Scholar]
  13. Jager D, Stockert E, Gure AO, et al. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res 2001; 61 : 2055–61. [Google Scholar]
  14. Di Modugno F, Bronzi G, Scanlan MJ, et al., Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer 2004; 109 : 909–18. [Google Scholar]
  15. Pallasch CP, Struss AK, Munnia A, et al., Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival. Int J Cancer 2005; 117 : 456–9. [Google Scholar]
  16. Prasannan L, Misek DE, Hinderer R, et al., Identification of beta-tubulin isoforms as tumor antigens in neuroblastoma. Clin Cancer Res 2000; 6 : 3949–56. [Google Scholar]
  17. Brichory FM, Misek DE, Yim AM, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA 2001; 98 : 9824–9. [Google Scholar]
  18. Klade CS, Voss T, Krystek E, et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001; 1 : 890–8. [Google Scholar]
  19. Lichtenfels R, Kellner R, Atkins D, et al., Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim Biophys Acta 2003; 1646 : 21–31. [Google Scholar]
  20. Lichtenfels R, Kellner R, Bukur J, et al. Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma. Proteomics 2002; 2 : 561–70. [Google Scholar]
  21. Unwin RD, Harnden P, Pappin D, et al. Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 2003; 3 : 45–55. [Google Scholar]
  22. Fujita Y, Nakanishi T, Hiramatsu M, et al. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 2006; 12 : 6415–20. [Google Scholar]
  23. Yang F, Xiao ZQ, Zhang XZ, et al., Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Proteome Res 2007; 6 : 751–8. [Google Scholar]
  24. Le Naour F, Brichory F, Misek DE, et al. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 2002; 1 : 197–203. [Google Scholar]
  25. Hong SH, Misek DE, Wang H, et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 2004; 64 : 5504–10. [Google Scholar]
  26. Le Naour F, Misek DE, Krause MC, et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 2001; 7 : 3328–35. [Google Scholar]
  27. Hanash S. Harnessing immunity for cancer marker discovery. Nat Biotechnol 2003; 21 : 37–8. [Google Scholar]
  28. Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 2005; 382 : 669–78. [Google Scholar]
  29. Gagnon A, Kim JH, Schorge JO, et al. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res 2008; 14 : 764–71. [Google Scholar]
  30. Feng Y, Ke X, Ma R, et al. Parallel detection of autoantibodies with microarrays in rheumatoid diseases. Clin Chem 2004; 50 : 416–22. [Google Scholar]
  31. Mattoon D, Michaud G, Merkel J, et al. Biomarker discovery using protein microarray technology platforms: antibody-antigen complex profiling. Expert Rev Proteomics 2005; 2 : 879–89. [Google Scholar]
  32. Ehrlich JR, Qin S, Liu BC. The reverse capture autoantibody microarray: a native antigen-based platform for autoantibody profiling. Nat Protoc 2006; 1 : 452–60. [Google Scholar]
  33. Miller JC, Zhou H, Kwekel J, et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 2003; 3 : 56–63. [Google Scholar]
  34. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353 : 1224–35. [Google Scholar]
  35. Qiu J, Madoz-Gurpide J, Misek DE, et al. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 2004; 3 : 261–7. [Google Scholar]
  36. Nam MJ, Madoz-Gurpide J, Wang H, et al. Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 2003; 3 : 2108–15. [Google Scholar]
  37. Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007; 18 : 868–73. [Google Scholar]
  38. Koziol JA, Zhang JY, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003; 9 : 5120–6. [Google Scholar]
  39. Zhong L, Peng X, Hidalgo GE, et al. Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer. Proteomics 2004; 4 : 1216–25. [Google Scholar]
  40. Lucchi G, Hendra JB, Pecqueur D, Ducoroy P. Vers une standardisation des outils pour les études de protéomique clinique. Med Sci (Paris) 2007; 23 (suppl 1) : 19–22. [Google Scholar]
  41. Solary E. Protéomique clinique en oncologie. Med Sci (Paris) 2007; 23 (suppl 1) : 3–4. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.